Registration
REGISTER FOR THE CONFERENCE
Apply to Exhibit
APPLICATION FOR EXHIBITION
Sponsorship
SPONSORSHIP APPLICATION
CGN Guangdong Taipingling Nuclear Power Project Unit 2 Officially Commences Commercial Operation
On August 3, CGN Guangdong Taipingling Nuclear Power Project Unit 2 officially commenced commercial operation, marking the full completion of the Phase I project of the first Hualong One self-developed third-generation nuclear power project in the Guangdong-Hong Kong-Macao Greater Bay Area. Located in Huidong County, Huizhou City, Guangdong Province, the Taipingling Nuclear Power Project's Phase I includes Units 1 and 2, which received national approval on April 8, 2019. Among them, Unit 1 of the project commenced commercial operation in April this year. The construction team fully leveraged experience from previous Hualong One projects, successively completing a series of major engineering milestones including nuclear island main structure construction, equipment installation and commissioning, nuclear fuel loading, first criticality of the reactor, and grid connection for power generation, with steady improvements in project construction quality, safety levels, and construction efficiency...
2026-08-03
Key Breakthroughs Achieved in Development of Core Equipment for BEST Compact Fusion Energy Test Facility
2026-08-03
Central Commission for Discipline Inspection and National Supervisory Commission: Toward Innovation and Green Development, Empowering All Industries with Nuclear Energy
2026-08-03
Pre-Startup Review (PSUR) for Sanmen Nuclear Power Plant Unit 3 Completed
2026-08-03
Japanese research team experimentally demonstrates that fusion plasma fluctuations can drive inward particle transport
2026-08-03
Wang Min, Deputy Director of the China International Nuclear Fusion Energy Program Execution Center, Led a Delegation to Thailand and Malaysia to Attend China-Thailand and China-Malaysia Bilateral Science and Technology Cooperation Consultations on Nuclear Fusion
2026-08-03
U.S. Nuclear Regulatory Commission (NRC) Proposed Rule to Update Radioactive Material Transport Regulations for New Reactor Technologies
2026-08-03
Global nuclear power generation hits record high in 2025, with net growth mainly driven by China
2026-08-03
Uzbekistan Updates Licensing Rules for Nuclear Energy and Ionizing Radiation Sources
2026-08-03
News of new energy vehicle fires occasionally surfaces, and the culprit is almost always the power battery. To fundamentally address this industry-wide problem, the mandatory national safety standard "Safety Requirements for Traction Battery of Electric Vehicles" will officially take effect on July 1, 2026, ushering in the strictest examination the battery industry has ever faced. Facing high-standard testing requirements, CGN Dasheng has deployed its full suite of non-destructive testing capabilities, leveraging precise and comprehensive non-destructive flaw detection technologies to help the industry deliver a high-standard safety answer sheet. The internal structure of a power battery is wound layer upon layer, resembling a Swiss roll. During production, subtle defects such as electrode foil wrinkles, metal debris contamination, and misalignment between positive and negative electrodes may occur. These "minor issues" can evolve into overheating,...
2026-08-04
The national mandatory safety standard "Safety Requirements for Traction Batteries for Electric Vehicles" officially takes effect on July 1, 2026, further raising the requirements for power battery safety inspection. In response to the needs for internal defect identification, fault tracing, and in-line production testing, CGN Dasheng Accelerator Technology Co., Ltd. has launched multiple nondestructive testing solutions, utilizing X-ray imaging, industrial CT, and electron beam scanning microfocus X-ray source technologies to provide inspection means for power battery quality control. The internal structure of power batteries is complex, with cells typically composed of multiple layers of materials wound or stacked. During production, subtle defects such as electrode plate wrinkles, metal debris contamination, positive-negative electrode misalignment, and welding porosity can...
2026-08-04
From July 30 to 31, Zhou Jiaxi, Director of the Institute of Radiation Medicine, Chinese Academy of Medical Sciences, Liu Qiang, Deputy Director, Su Xu, Distinguished Professor, along with relevant heads from the National Nuclear Radiation Medical Treatment Base (Tianjin), the Science and Technology Department, and the Industry Department, successively visited Shanghai Pulmonary Hospital and the Affiliated Hospital of Jiangnan University for cooperation exchanges, and jointly inaugurated the two joint laboratories for radiation injury treatment. On the afternoon of July 30, the plaque presentation ceremony for the joint laboratory between the Institute of Radiation Medicine and Shanghai Pulmonary Hospital was held in Shanghai. Chen Chang, Deputy Secretary of the Party Committee and President of Shanghai Pulmonary Hospital, Liu Haipeng, Vice President, and heads of relevant departments attended the event. Zhou Jiaxi stated that the co-establishment of the joint laboratory is a...
2026-08-04
Recently, the public notice period for the review results of applications for the Innovative Medical Device Special Review Program by the Center for Medical Device Evaluation of the National Medical Products Administration has concluded. The ultra-high dose rate electron beam radiotherapy system (e-Flash 200A), independently developed by Zhongji Flash Medical Technology Co., Ltd., has officially entered the Innovative Medical Device Special Review Program. According to reports, the e-Flash 200A is China's first ultra-high dose rate electron beam FLASH radiotherapy device and had previously been included in the "Global New" green channel. Its entry into the Innovative Medical Device Special Review Program signifies further recognition of the product's technological innovation and clinical application value. The system is designed for superficial tumor radiothe...
2026-08-04
To thoroughly implement the Ecological Environment Code and further enhance radiation safety management in the field of nuclear technology utilization, the 2026 Special Training Course on the Application of the Ecological Environment Code and Radiation Safety Practices for Nuclear Technology Utilization, hosted by the Nuclear and Radiation Safety Center of the Ministry of Ecology and Environment (hereinafter referred to as the Center), was successfully held in Xi'an, Shaanxi Province, from July 27 to 30. Nearly one hundred trainees from 67 institutions nationwide, including ecological environment departments, research institutes, medical facilities, and environmental impact assessment (EIA) compilation agencies, gathered together to study the new regulations and discuss practical matters, empowering the industry's high-quality development. This training closely followed the pulse of industry development, focusing on the new situations and challenges...
2026-08-03
The General Department of Customs and Excise of Cambodia recently organized a delegation for a working visit to Jiangsu Province, China, focusing on smart customs development and advanced scanning inspection technologies, with the aim of advancing Cambodia's customs modernization reform and digital transformation, enhancing trade facilitation and customs supervision capacity. According to the General Department of Customs and Excise of Cambodia, from July 27 to 31, Kun Nhem, Special Representative of the Cambodian Prime Minister and Director General of Customs and Excise, led a delegation to visit Jiangsu Province and conducted an inspection and exchange at Nuctech Company Limited. The visit was intended to understand the application of smart customs systems and customs inspection technologies in actual operations, in support of Cambodia's Customs Reform...
2026-08-03
Ratio Therapeutics, Inc., a U.S. clinical-stage pharmaceutical company, recently announced the completion of a $70 million Series C financing round. The company stated that following this round, its cumulative total financing has exceeded $240 million. According to the announcement, this round saw participation from existing investors Duquesne Family Office and Bristol Myers Squibb, while also bringing in new investors such as Catalio Capital Management, Eli Lilly and Company, and Wasatch Group. Ratio Therapeutics stated that the proceeds will be used to advance the clinical development of its targeted radiotherapeutic product pipeline and expand manufacturing infrastructure. The company plans to continue advancing the ATLAS study, which is evaluating its lead radiotherapeutic agent [Ac-2...
2026-08-03
